您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Study Results Show That Oral Contraceptives/Hormone Replacement Therapy May Protect Against Brain Aneurysms(2)
本文章共3260字,分2页,当前第2页,快速翻页:


 

In both groups, strong similarities existed across multiple screening factors. The median age of both groups was 53, and when comparing for pertinent criteria, the results were as follows: body mass index, 27.1 for case group and 25.2 for control group; average age of menstrual onset, 13 years for both groups; the incidence for those who never had children, 15 percent for case group and 13 percent for control group; and the incidence for those whose first pregnancy occurred over 30 years of age, 10 percent for case group and 11 percent for control group. Where it concerned use of estrogen modifying agents, however, the results took a notable turn between the two groups. The rate of OC usage was 60 percent for the case group as compared to 77.6 percent for the control group; the rate of HRT usage was 23.7 percent for the case group and 44.8 percent for the control group. Furthermore, when comparing median duration of OC use, results showed 2.6 years for the case group and 5.2 years for the control group.
 

According to Chen, these differences in the usage of estrogen modifying agents qualify as statistically significant and indicate that women with brain aneurysms not only used OC and HRT less frequently than the general population, but if they did, in the case of OC, it was of shorter duration. It is reasonable to conclude, said Chen, that these results, therefore, support the hypothesis that drops in estrogen that occur in menstruation and particularly at menopause may explain why cerebral aneurysms are more frequently found in women, particularly at menopause.
 

"For neurointerventional practitioners, this study provides yet another piece of evidence that estrogen stabilization may play a protective role in women who are at risk for brain aneurysms," said Chen. Currently, Chen and his colleagues are designing more studies that will further examine the effects of estrogen on the blood vessels in the brain.
 

About SNIS
 

SNIS members are neurointerventional practitioners with backgrounds in neuroradiology, neurosurgery and neurology that come together in the shared discipline of neurointerventional surgery. Our practitioners specialize in minimally invasive and endovascular procedures to treat stroke, aneurysms, carotid stenosis and spine fractures. Over the past two decades, our physicians have made numerous contributions to the neurosciences including: advancing stroke treatment through catheter based therapy; innovating endovascular coiling for aneurysms; pioneering interventional procedures to treat fractures in the spine; and initiating the first-ever stroke registry to track procedural success in the treatment of acute stroke. More information on SNIS and our members' treatment specialties may be found at www.snisonline.org.
 

Source: Society of NeuroInterventional Surgery

CONTACT: Rebecca Hall, Media Relations, SNIS, +1-305-519-2094
 

Web Site: http://www.snisonline.org/
 

转载自pharmaLive

 


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  Basilea Pharmaceutica AG (CH) - Data on

  Orexigen Therapeutics Announces Publicat

  Geron to Proceed with First Human Clinic

  Bionovo to Advance Menerba to Phase 3 Cl

  deCODE Shows how Genetic Risk of Kidney

  New pathway to Parkinson's and Alzheimer

  Plant Compound Resveratrol Shown to Supp

  WaferGen Announces Purchase of SmartChip

  Researchers Solve Mystery of Uner Tan Sy

  Shionogi Inc. Announces FDA Approval of

勃林格殷格翰糖尿病药物linagliptin一项Ⅲ期

厄洛替尼在欧盟提交申请用于具EGFR 活化突变

诺华公司肾癌治疗药物依维莫司新适应证研究

罗氏发布在研糖尿病药taspoglutide的Ⅲ期临

罗氏正式提交赫赛汀第二代共轭化合物曲妥珠

达沙替尼申请用于慢性髓性白血病一线治疗

动脉血管瘤支架有望成为新一代畅销介入治疗

相关评论

    
本文章所属分类:首页 研发动态